Dimensional Fund Advisors’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,240
Closed -$96.8K 3521
2023
Q1
$96.8K Sell
1,240
-93
-7% -$10.8K ﹤0.01% 3307
2022
Q4
$111 Hold
1,333
﹤0.01% 3312
2022
Q3
$123K Sell
1,333
-435
-25% -$56.1K ﹤0.01% 3308
2022
Q2
$264K Sell
1,768
-1,165
-40% -$213K ﹤0.01% 3208
2022
Q1
$711K Hold
2,933
﹤0.01% 3073
2021
Q4
$887K Sell
2,933
-34
-1% -$10.9K ﹤0.01% 3055
2021
Q3
$1.23M Hold
2,967
﹤0.01% 2996
2021
Q2
$909K Buy
2,967
+262
+10% +$57.5K ﹤0.01% 3046
2021
Q1
$555K Buy
2,705
+365
+16% +$79.8K ﹤0.01% 3123
2020
Q4
$468K Buy
2,340
+44
+2% +$9.15K ﹤0.01% 3099
2020
Q3
$380K Buy
2,296
+355
+18% +$80.8K ﹤0.01% 3115
2020
Q2
$481K Buy
1,941
+739
+61% +$173K ﹤0.01% 3081
2020
Q1
$219K Sell
1,202
-661
-35% -$167K ﹤0.01% 3197
2019
Q4
$540K Sell
1,863
-2,535
-58% -$703K ﹤0.01% 3126
2019
Q3
$1.2M Hold
4,398
﹤0.01% 2975
2019
Q2
$1.65M Buy
4,398
+803
+22% +$240K ﹤0.01% 2945
2019
Q1
$964K Buy
3,595
+1,837
+104% +$436K ﹤0.01% 3041
2018
Q4
$374K Buy
+1,758
New +$545K ﹤0.01% 3188

Other funds holding PVLA

Dimensional Fund Advisors's PVLA Position: Q2 2023 in Review

Dimensional Fund Advisors sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 1,240 shares — an estimated $96.8K sold.

Dimensional Fund Advisors first reported a position in PVLA in Q4 2018 and held it in 18 quarters. The position peaked at $1.65M in Q2 2019. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Dimensional Fund Advisors reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,240 Palvella Therapeutics shares in Q2 2023, an estimated $96.8K.
  • Dimensional Fund Advisors first reported a position in Palvella Therapeutics in Q4 2018 and held it in 18 quarters.
  • Dimensional Fund Advisors's Palvella Therapeutics position peaked at $1.65M in Q2 2019.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Dimensional Fund Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.